225 related articles for article (PubMed ID: 30928569)
1. Mortality impact of empirical antimicrobial therapy in ESBL- and AmpC-producing Enterobacteriaceae bacteremia in an Australian tertiary hospital.
Lim CL; Spelman D
Infect Dis Health; 2019 Aug; 24(3):124-133. PubMed ID: 30928569
[TBL] [Abstract][Full Text] [Related]
2. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
3. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
[TBL] [Abstract][Full Text] [Related]
4. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
[TBL] [Abstract][Full Text] [Related]
5. [Bacteraemia due to extended-spectrum beta-lactamases (ESBL) and other beta-lactamases (ampC and carbapenemase) producing Enterobacteriaceae: association with health-care and cancer].
García-Gómez M; Guío L; Hernández JL; Vilar B; Pijoán JI; Montejo JM
Rev Esp Quimioter; 2015 Oct; 28(5):256-62. PubMed ID: 26437756
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia.
Menashe G; Borer A; Yagupsky P; Peled N; Gilad J; Fraser D; Riesenberg K; Schlaeffer F
Scand J Infect Dis; 2001; 33(3):188-93. PubMed ID: 11303808
[TBL] [Abstract][Full Text] [Related]
7. Appropriateness of empirical antibiotic prescription for bloodstream infections in an emergency department from 2006 to 2018: impact of the spread of ESBL-producing Enterobacterales.
Clemenceau M; Ahmed-Elie S; Vilfaillot A; Chocron R; Compain F; Lebeaux D; Grohs P
Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):71-77. PubMed ID: 34553311
[TBL] [Abstract][Full Text] [Related]
8. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
Huang SS; Lee MH; Leu HS
J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae blood isolates with inducible AmpC β-lactamase.
Cheong HS; Ko KS; Kang CI; Chung DR; Peck KR; Song JH
Microb Drug Resist; 2012 Aug; 18(4):446-52. PubMed ID: 22409779
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.
Khoo AL; Zhao YJ; Teng M; Ying D; Jin J; Chee YL; Poon LM; Lim SE; Koh LP; Chng WJ; Lim BP; Hsu LY; Chai LYA
Int J Antimicrob Agents; 2018 Sep; 52(3):350-357. PubMed ID: 29751120
[TBL] [Abstract][Full Text] [Related]
11. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
Sfeir MM; Askin G; Christos P
Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
[TBL] [Abstract][Full Text] [Related]
12. Does Quick Sepsis-Related Organ Failure Assessment Suggest the Use of Initial Empirical Carbapenem Therapy in Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Bacteria? :A Multicenter Case-Control Study.
Mitsuboshi S; Tsuruma N; Watanabe K; Takahashi S; Nakashita M; Ito A; Kobayashi K; Tsugita M
Jpn J Infect Dis; 2019 Mar; 72(2):124-126. PubMed ID: 30381688
[TBL] [Abstract][Full Text] [Related]
13. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.
Marchaim D; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Sprecher H; Lachish T; Wiener-Well Y; Alon D; Chowers M; Ciobotaro P; Bardenstein R; Paz A; Potasman I; Giladi M; Schechner V; Schwaber MJ; Klarfeld-Lidji S; Carmeli Y
Antimicrob Agents Chemother; 2010 Dec; 54(12):5099-104. PubMed ID: 20837757
[TBL] [Abstract][Full Text] [Related]
14. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
15. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Russo A; Falcone M; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Cisneros JM; Hernández-Torres A; Farcomeni A; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Rodriguez-Gomez J; Souli M; Bonomo RA; Paterson DL; Carmeli Y; Pascual A; Rodríguez-Baño J; Venditti M;
Int J Antimicrob Agents; 2018 Nov; 52(5):577-585. PubMed ID: 29969692
[TBL] [Abstract][Full Text] [Related]
16. Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study.
Noguchi T; Matsumura Y; Yamamoto M; Nagao M; Takakura S; Ichiyama S
BMC Infect Dis; 2017 Jan; 17(1):44. PubMed ID: 28061869
[TBL] [Abstract][Full Text] [Related]
17. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward.
Meini S; Laureano R; Tascini C; Arena F; Fani L; Frullini A; Passaleva MT; Roberts AT; Mannini D; Sbrana F; Ripoli A; Rossolini GM
Eur J Intern Med; 2018 Feb; 48():50-56. PubMed ID: 29089174
[TBL] [Abstract][Full Text] [Related]
20. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.
Frakking FN; Rottier WC; Dorigo-Zetsma JW; van Hattem JM; van Hees BC; Kluytmans JA; Lutgens SP; Prins JM; Thijsen SF; Verbon A; Vlaminckx BJ; Cohen Stuart JW; Leverstein-van Hall MA; Bonten MJ
Antimicrob Agents Chemother; 2013 Jul; 57(7):3092-9. PubMed ID: 23612198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]